Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Ultragenyx Pharma (RARE) Misses Q1 EPS by 36c
May 6, 2020 5:54 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.05), $0.36 worse than the analyst estimate of ($1.69). Revenue for the quarter came in at $36.31 million versus the consensus estimate of $36.58 million.
The global coronavirus pandemic has created unprecedented challenges for the world at... More
